ChartRow logo
Data provided bySource: Twelve Data
PeersNBIXTEVARDYELANKMBUTHR
Share this page

VTRS — Viatris Inc. price, chart and key statistics

Technical analysis2
Overlay lines0
Addendum charts0
Data provided bySource: Twelve Data
What would $1,000 invested in VTRS be worth today? →
VTRS returns: By year · By month · By week · Trailing

Price data

Price
$19.91
YTD price return
+59.92%
YTD total return
+63.69%
Market cap
22.8B
Enterprise value
34.6B
Shares outstanding
1.1B
52W low
$9.92
52W high
$19.96
From 52W high
-0.25%
From 52W low
+100.71%
52W range
100%$9.92–$19.96
Beta
0.90

Volume

Rel volume
1.56×
30D volume
9.2M
30D $ vol
169.1M

Insider trading

Insider net 1W
none
Insider net 1M
none
Insider net 3M
none
Insider net 1Y
−$1.1M

Form 4 transactions by trade date, as filed; latest on file 2026-06-25.

Fundamentals

Sales (ttm)
14.7B
Sales/share
$12.85
FCF (ttm)
2.1B
FCF/share
$1.84
Book value/share
$11.94
Debt / equity
0.85×
Current ratio
1.55

Growth (CAGR, ttm) · 10Y

Sales
+4.27%-1.62%-3.02%n/a
FCF
+27.15%+0.19%-0.40%n/a
Shares
-0.46%-1.50%-1.06%n/a

Per-share growth (CAGR, ttm) · 10Y

Sales/share
+4.75%-0.12%-1.98%n/a
FCF/share
+27.74%+1.71%+0.67%n/a
Book value/share
-9.66%-11.79%-7.35%n/a
Dividend/share
+0.00%+0.00%+8.21%n/a
Price
+97.03%+29.29%+7.71%-5.48%
Total return
+104.02%+34.84%+12.34%-3.33%

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/OI (ttm)
135.6×
Fwd P/E
7.0×
P/S (ttm)
1.5×
P/B (mrq)
1.7×
P/FCF (ttm)
10.8×
EV/EBITDA (fy)
12.3×
EV/Sales (ttm)
2.4×
FCF yield (ttm)
9.25%
Dividend yield (fwd)Div yield
2.41%
Dividend yield (ttm)
2.41%
Dividend/share (fwd)
$0.48
Buyback yield (realized, 1y)
0.46%
Shareholder yield (realized, 1y)
2.87%
Buyback yield (cash, ttm)
1.68%
Shareholder yield (cash, ttm)
1.68%

Vs own 10Y history

P/OI
92nd
P/S
100th
P/B
100th
P/FCF
94th

Bar = where today’s multiple sits in VTRS’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).

Performance · price returntotal return · as of 2026-11-06#

Data provided bySource: Twelve Data
1D
+4.96%
5D
+4.57%
1M
+13.51%
3M
+22.22%
YTD
+59.92%
1Y
+96.93%
5Y
+45.01%
1D
+4.96%
5D
+4.57%
1M
+13.51%
3M
+23.14%
YTD
+63.69%
1Y
+103.92%
5Y
+78.95%

Fundamentals#

Revenue

5Y CAGR +3.7%5Y CAGR +3.7%YoY −0.3%
$14.7B TTM$3.7B Q3 '26
FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Operating income

5Y n/m5Y n/mYoY +46.3%
−$4.6M TTM$261.5M Q3 '26
FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

EPS (diluted)

5Y n/m5Y n/mYoY n/m
−$3.00 FY25−$0.28 Q3 '26
FY18FY19FY20FY21FY22FY23FY24FY25
Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Free cash flow

5Y CAGR +14.4%5Y CAGR +14.4%YoY +23.6%
$2.1B TTM$813.7M Q3 '26
FY18FY19FY20FY21FY22FY23FY24FY25TTM

TTM: operating cash flow $2.5B, capex −$374.9M

Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Q3 2026: operating cash flow $899.4M, capex −$85.7M

Shares (diluted)

5Y +133.7%5Y +133.7%YoY −1.4%
1.1B TTM1.1B Q3 '26
FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Dividend per share

YoY +0.0%
$0.48 TTM$0.12 Q3 '26
FY21FY22FY23FY24FY25TTM
Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Full VTRS financials →

Viatris Inc. is a global healthcare company that develops, manufactures, and markets prescription medicines across a broad range of therapeutic areas. Its portfolio includes branded medicines, generic drugs, complex generics, and biosimilars, serving patients and healthcare providers in developed and emerging markets. The company also supplies active pharmaceutical ingredients used in pharmaceutical manufacturing and supports access to medicines through broad commercial and distribution capabilities. Viatris Inc. operates across regions including North America, Europe, Greater China, Japan, Australia, New Zealand, Latin America, Africa, and the Middle East. Its products address conditions in areas such as cardiovascular health, infectious diseases, central nervous system disorders, immunology, and oncology. By combining established brands with off-patent and technically complex medicines, Viatris Inc. occupies an important role in the global pharmaceutical market, helping manufacturers, healthcare systems, and patients access a wide range of essential treatments.

Canonsburg, PA·30,000 employees·Drug Manufacturers - Specialty & Generic·viatris.com·As of Oct 28, 2026

Recent filings#

All filings and insider trades →

ETFs holding VTRS#

31 of the 193 ETFs ChartRow carries live hold VTRS. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).

FundNameFiled weight
SPYDSPDR Portfolio S&P 500 High Dividend ETF1.5%
COWZPacer US Cash Cows 100 ETF0.5%
VBRVanguard Small-Cap Value ETF0.4%
XLVHealth Care Select Sector SPDR Fund0.3%
VHTVanguard Health Care ETF0.3%
VBVanguard Small-Cap ETF0.2%
RSPInvesco S&P 500 Equal Weight ETF0.2%
IWSiShares Russell Mid-Cap Value ETF0.2%
TickerName1M1D
LLYEli Lilly and Company+16.98%-0.79%
JNJJohnson & Johnson+8.42%+1.43%
ABBVAbbVie Inc.+9.23%+1.07%
MRKMerck & Co. Inc.+3.37%-0.14%
UNHUnitedHealth Group Incorporated Common Stock (DE)+4.74%-0.40%
NVSNovartis AG+15.46%+0.38%
TMOThermo Fisher Scientific Inc.+5.81%+2.63%
AMGNAmgen Inc.+14.36%+0.03%